FOCUS-C9 Clinical Trial Advances; Complete Data Due 1st Half 2023

Results of Phase 3 Trial of TUDCA in Slowing ALS Likely Next Year

An ongoing Phase 3 clinical trial in Europe is testing whether tauroursodeoxycholic acid, added to standard therapy, can slow disease progression and extend survival among people with amyotrophic lateral sclerosis (ALS). The oral compound, also known as TUDCA, is one of the two ingredients in Relyvrio (sodium phenylbutyrate…

I’m Learning to Embrace My High-speed ALS Reflexes

Shortly after I was diagnosed with ALS, I began to notice my reflexes acting kind of wonky. Pre-ALS, thanks to years of practicing yoga and tai chi, I considered myself a relatively calm and relaxed person. But now, any sudden loud noise or unexpected tap on my shoulder had…